Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of TGTX-101 for the treatment of GM2-Gangliosidosis

Next Previous
X
Search
Trial Profile

Phase I/II study of TGTX-101 for the treatment of GM2-Gangliosidosis

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TSHA 101 (Primary)
  • Indications GM2 gangliosidoses
  • Focus Adverse reactions

    • Most Recent Events

    • 10 Mar 2021 New trial record
    • 03 Mar 2021 According to a Taysha Gene Therapies media release, the company expects to submit an Investigational New Drug (IND) application in the U.S. in the second half of 2021 and initiate this in the 2H 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top